Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9UPQ4

UPID:
TRI35_HUMAN

ALTERNATIVE NAMES:
Hemopoietic lineage switch protein 5

ALTERNATIVE UPACC:
Q9UPQ4; Q86XQ0; Q8WVA4

BACKGROUND:
The E3 ubiquitin-protein ligase TRIM35, alternatively named Hemopoietic lineage switch protein 5, is integral to various biological processes including the innate immune response, cell death, and glucose metabolism. It facilitates 'Lys-63'-linked polyubiquitination of TRAF3, crucial for type I interferon production through the RIG-I signaling pathway. TRIM35 also targets viral proteins for 'Lys-48'-linked polyubiquitination and subsequent degradation, and regulates TLR7- and TLR9-mediated signaling by promoting 'Lys-48'-linked ubiquitination and degradation of IRF7.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifunctional role of E3 ubiquitin-protein ligase TRIM35 offers a promising avenue for developing novel therapeutic interventions, particularly in the realm of infectious diseases and immune regulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.